Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT07108309 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer

Name: BCD-236 in Combination With Chemotherapy in Patients With Relapsed and/or Metastatic Triple Negative Breast Cancer — clinical trial record (NCT07108309)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

Study acronym: AREAL

StatusRecruiting

PhasePhase 2

SponsorBiocad

Started2024-07-15

View on ClinicalTrials.gov ↗

Record status

This record was last updated August 7, 2025 (before its estimated December 2025 completion). Its status may not reflect the trial's current state.

Biocad

26 trials monitored

See all monitored trials

Breast Cancer

5,180 trials monitored

See 256 trials at risk

Triple-Negative Breast Cancer

594 trials monitored

See 37 trials at risk

To study the efficacy, safety, pharmacokinetics and immunogenicity of BCD-236 in combination with chemotherapeutic agents (CHT) in 2nd and subsequent lines of therapy of subjects with relapsed and/or metastatic triple negative breast cancer (TNBC).

Trial Details

NCT Number	NCT07108309
Lead Sponsor	Biocad
Conditions	Triple Negative Breast Cancer
Enrollment	124 participants
Start Date	2024-07-15
Primary Completion	2025-12 (estimated)
Study Completion	2027-05 (estimated)
Updated on ClinicalTrials.gov	2025-08-07